Isodiol Launches New CBD Products

Isodiol International Inc., a leading bioactive cannabidiol (CBD) innovator, is launching three new CBD products. The company has developed these products with Level Brands Inc. (LEVB). Level Brands is a licensed marketing and brand management company.

The three new products include a CBD pain-relieving cream, a CBD oral spray, and CBD edibles. The company will market these three products under Ireland Men One (I’M1), BeTrū | Kathy Ireland Health & Wellness, and Chef Andre Carthen Edibles, respectively.

The products will be available at stores and online retailers across the nation by early summer 2018.

Both Isodiol and Level Brands extended their license agreement to 10 years in January 2018. Under this agreement, the companies will work together to develop novel products for I’M1, Kathy Ireland, Chef Andre Carthen, and Nicholas Walker. Kathy Ireland, Chef Andre Carthen, and Nicholas Walker are licensors to Level Brands. On the other hand, I’M1 is a lifestyle brand for millennial men and is a subsidiary of LEVB.

With this strategic partnership, Isodiol is successfully introducing highly bioactive CBD products into the market. The huge network and consumer base of Kathy Ireland are further helping the company expand its reach and presence. The company is targeting mainstream channels to help people around the globe understand the benefits of CBD.

On the other hand, Kathy Ireland’s main aim is to push Isodiol as a leading CBD company worldwide. The company firmly believes that the CBD industry is poised to grow in the next decade. Together, Isodiol and Level Brands want to promote and create awareness that CBD has immense therapeutic benefits. The companies plan to keep working to develop premium-quality CBD products with no psychoactive component.

CBD is a non-psychoactive component of the medical cannabis plant. It has therapeutic features to treat diseases like pain, inflammation, cancer, sclerosis, and epilepsy. The CBD market is expected to become a $2.1 billion industry by 2020, says a market report by The Hemp Business Journal.


Read more: ‘CBD: The Biotech Boom Investors Haven’t Woken Up To Yet’

Leave a Reply

Your email address will not be published.